Skip to main content
Home
  • Solutions
    Clinical solutions
    Blended Solutions Cardiac Safety Solutions Clinical & Scientific Operations Decentralised Clinical Trials Early Clinical Laboratories Medical Imaging Site & Patient Solutions Strategic Solutions
    Consulting & Commercial
    Asset Development Consulting Commercial Positioning Language Services Outcome Measures Real World Intelligence Regulatory Affairs Symphony Health data
    meeting
    Case studies

    Reducing time to market, delivering on quality, providing deep therapeutic expertise and enhancing R&D ROI.

    Innovative research tools showcase
    Technologies

    Technology solutions from early phase through to post-marketing.

  • Sectors
    Sectors

    ICON provides its full range of clinical, consulting and commercial services across several industry sectors.

    Read more
    Biotech Government and Public Health Medical Device Pharmaceuticals
    Biotechnology services navigation panel
    Biotech

    Developing transformative therapies requires a flexible approach.

    Employee engagement program overview
    ICON and You

    Partners making a difference.

  • Therapeutics
    Therapeutics
    Cardiovascular Central Nervous System Endocrine & Metabolic Disorders Hepatology Infectious Diseases Internal Medicine & Immunology Oncology
    Cross-therapeutics
    Biosimilars Cell and Gene Therapies Medical Device Pediatrics Rare & Orphan Diseases Vaccines Women's Health
    Obesity 2025 insights image
    Obesity

    A focus on combination therapies requires appropriate obesity-specific trial designs, long-term follow-up studies and diverse patient recruitment.

    Biological research visual element
    Therapeutics insights

    ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.

  • Insights
    Insights
    Digital Disruption Patient Centricity Regulatory Intelligence Therapeutics insights Transforming Trials Value Based Healthcare Blog Videos Webinar Channel
    systematic_literature_reviews_whitepaper
    Demystifying the SLR: “S” stands for systematic

    A structured approach to evidence-based decision-making.

    biosimilars and oncology
    The future of oncology biosimilars

    Considerations for development through 2040.

    icons connected through network_artificail_intelligence
    Decoding AI in software as a medical device (SaMD)

    Regulatory insights and market strategies.

  • News & Events
    News & Events

    ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.

    Read more
    Press releases In the News Mediakit Awards Events Webinars Social media
    webinar
    Enhancing clinical trials in obesity by integrating COAs and DHTs

    7 October 2025. Register now.

    whitepaper CNS
    Boosting clinical trial success in Alzheimer’s, Parkinson’s and other neurodegenerative diseases

    22 October 2025. Register now.

  • About ICON
    About ICON
    Company history ICON at a glance Healthcare Intelligence ICON in Asia Pacific ICON in Latin America Leadership Quality
    ICON for
    Patients Volunteers Investigators Jobs & Careers Investors Suppliers
    Responsible business practice indicators
    Sustainability, charity, inclusion and belonging

    ICON Cares is our commitment to making a positive impact on our people, environment and our community.

    Medical analytics presentation preview
    Healthcare Intelligence

    Clinical Research. Evolved.

  • Careers
  • Investors
  • Contact
  • 日本語
  • 简体中文
  1. Home
  2. Insights
  3. Blog page
  4. Developing Digital Biomarkers from Raw Accelerometer Data

Developing Digital Biomarkers from Raw Accelerometer Data

Page tools
Share Share
Facebook

Share on Facebook

Facebook

Share on X

Facebook

Share on Linkedin

Bluesky

Share on Bluesky

  • 02 May 2024

Accelerometers have the ability to capture significant quantities of raw data, potentially containing patterns which, if discoverable, could be used to quantify specific motor movements. The ability to detect such movements has value in identifying periods of tremor or other neuromuscular disorder.

We conducted a proof of concept for developing digital biomarkers from raw accelerometer data that we presented as a poster entitled 'Proof of Concept for the Development of Digital Biomarker using Raw Accelerometer Data' from a Wrist Worn Device at the DIA US meeting in 2016.

There is increasing interest in the use on accelerometer based wrist-worn devices in clinical trials. What isn’t well know is that wearables have been around for over 40 years with the first research papers citing the use of accelerometer based wrist-worn devices to capture human activity and sleep patterns appearing in the 1970’s.

Accelerometers are electromechanical devices that measure acceleration forces. They have a wide variety of applications and are found in phones, in drones for flight stabilisation, are used by seismologists to detect earthquakes and are key components in the deployment of air bags where they are used to detect car crashes.

The most common types used in wearables today are triaxial MEMS accelerometers;  small micro electro-mechanical systems (MEMS), that measure acceleration in 3 dimensions and are very sensitive to human motor movements.

These devices are capable of sampling up to 100 hertz- which results in 100 data points been collected every second. Potentially one device worn continuously for 7 days could produce 60million datasets. The management of this level of data was beyond both the memories and the analytics capabilities of these devices.

Originally the data generated was compressed and filtered by on-board firmware into epochs of 30seconds[1]*. This pre-processing significantly reduces the amount of data so in the example above, where the device is worn for 7 days, the output is  20 thousand datasets rather than 60 million. 

This is still a sizable amount and further analysed by validated algorithms generates discrete sleep and activity endpoints. From a data management perspective, within a clinical trial, the data from accelerometers can be managed in a similar fashion to blood pressure or temperature with 7 days of accelerometer data producing a finite number of clinically relevant endpoints.

The use of accelerometer data in this manner is well established, although limited to researchers and clinicians, focusing on the quantification of physical activity and sleep patterns. What is less well understood is the additional value that potentially exists in the raw accelerometer data, which may have potential in the monitoring and assessment of specific motor movements such as tremor.

For this experiment we selected tooth-brushing as a surrogate for tremor as it was easy to reproduce the action and the movement was discrete and finite. Context is essential in the management of raw data and we used a diary to timestamp the periods of interest, this allows for the identification of the signal of interest.

The training data used to generate the algorithms was different to the data periods that were tested. A set of classical machine models (decision trees, random forest, etc.) were built on the training dataset. A number of algorithms were identified and tested the best one had a positive predicative value of 0.9991.      

This Proof of concept has demonstrated that it is possible to use machine learning techniques to train a classification model from summarized raw accelerometer data to identify periods of specific movement patterns. There are issues regarding scalability but the potential value of accelerometer based devices to provide insights into human physical behaviours is considerable.

The advent of Artificial Intelligence and machine learning platforms will transform the ability of these devices to identity new and exploratory endpoints in patients with neuromuscular disease. This approach has potential application in objectively measuring motor movement events in neuromuscular disorders but also in the development of unique personal digital fingerprints. 

 

Reference:
[1] Other epochs can be selected, earlier models generated data in 1 minute epochs,  30 seconds are most common in sleep studies, with shorter epochs used in the assessment of physical activity.

In this section
In this section
  • Digital Disruption
    • Clinical strategies to optimise SaMD for treating mental health
    • Digital Disruption: Surveying the industry's evolving landscape
    • AI and clinical trials
      • Impact of AI on Outcomes Based Contracting
      • Using AI for site ID and selection
      • Applying AI to manage the risks and costs of postmarketing requirements
      • Integrating AI into Clinical Research: How AI is Enhancing Clinical Development
    • Clinical trial data anonymisation and data sharing
    • Clinical Trial Tokenisation
    • Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
    • Digital disruption in biopharma
    • Disruptive Innovation
    • mHealth wearables
      • Bring Your Own Device
      • Cybersecurity
        • Addressing cybersecurity for your medical device
      • Digital Endpoints
      • Transforming Medical Device Development with mHealth
    • Personalising Digital Health
    • Real World Data
      • Harnessing technology to maximise Real World Evidence value
      • Meeting Evidentiary Needs with EHRs
      • Post-Market Surveillance for Medical Devices
    • The triad of trust: Navigating real-world healthcare data integration
    • Decoding AI in software as a medical device (SaMD)
    • Software as a medical device (SaMD)
  • Patient Centricity
    • Agile Clinical Monitoring
    • Capturing the voice of the patient in clinical trials
    • Charting the Managed Access Program Landscape
    • Developing Nurse-Centric Medical Communications
    • Representation and inclusion in clinical trials
      • Diversity and inclusion in clinical trials whitepaper
    • Exploring the patient perspective from different angles
    • Patient safety and pharmacovigilance
      • A guide to safety data migrations
      • Taking safety reporting to the next level with automation
      • Outsourced Pharmacovigilance Affiliate Solution
      • The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
      • Sponsor and CRO pharmacovigilance and safety alliances
      • Understanding the Periodic Benefit-Risk Evaluation Report
    • Patient voice survey
    • Patient Voice Survey - Decentralised and Hybrid Trials
    • Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
    • Using longitudinal qualitative research to capture the patient voice
    • Prioritising patient-centred research for regulatory approval
  • Regulatory Intelligence
    • Accelerating access
    • Navigating the regulatory landscape in the US and Japan:
    • An innovative approach to rare disease clinical development
    • EU Clinical Trials Regulation
      • EMA guideline on computerised systems and electronic data in clinical trials
      • EU CTR Whitepaper
    • Using innovative tools and lean writing processes to accelerate regulatory document writing
    • Current overview of data sharing within clinical trial transparency
    • Global Agency Meetings: A collaborative approach to drug development
    • Keeping the end in mind: key considerations for creating plain language summaries
    • Navigating orphan drug development from early phase to marketing authorisation
    • Procedural and regulatory know-how for China biotechs in the EU
    • RACE for Children Act
    • Early engagement and regulatory considerations for biotech
    • Regulatory Intelligence Newsletter
    • Requirements & strategy considerations within clinical trial transparency
    • Spotlight on regulatory reforms in China
    • Demystifying EU CTR, MDR and IVDR
    • Transfer of marketing authorisation
    • Exploring FDA guidance for modern Data Monitoring Committees
    • Streamlining dossier preparation
  • Therapeutics insights
    • Endocrine and Metabolic Disorders
    • Cardiovascular
      • Mitigating the impact of COVID-19 on cardiovascular trials
    • Cell and Gene Therapies
      • Approaching the CAR T-cell therapy horizon
      • Cell and Gene ebook
      • Long-term follow-up studies of cell and gene therapies
      • Mainstreaming Cell & Gene Therapies
    • Central Nervous System
      • A mind for digital therapeutics
      • Challenges and opportunities in traumatic brain injury clinical trials
      • Challenges and opportunities in Parkinson’s Disease clinical trials
      • Early, precise and efficient; the methods and technologies advancing Alzheimer’s and Parkinson’s R&D
      • Key Considerations in Chronic Pain Clinical Trials
      • ICON survey report: CNS therapeutic development
    • Glycomics
    • Infectious Diseases
      • Antimicrobial Resistance
      • Considerations for strengthening vaccine development
      • COVID-19 vaccine trials
      • COVID-19 vaccines: Post-authorisation safety surveillance
      • HIV
      • The value of dynamic transmission models
    • NASH
      • The voice of NASH investigators
    • Obesity
      • Addressing obesity's impact across the disease spectrum
      • Trends and challenges in obesity research and clinical trials
      • Obesity and beyond: embracing multi-indication potential during clinical development
      • Survey report: How today’s obesity developers are navigating a multi-indication landscape
    • Oncology
      • ICON survey report: Innovation in Oncology
      • De-risking clinical development of precision medicines in oncology
      • Advances in imaging biomarkers: Estimating drug efficacy with tumour growth rate modelling
      • The future of oncology biosimilars
    • Paediatrics
      • Paediatric Risk Assessment Map
    • Respiratory
    • Rare and orphan diseases
      • Advanced therapies for rare diseases
      • Cross-border enrollment of rare disease patients
      • Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
      • Diversity, equity and inclusion in rare disease clinical trials
      • Identify and mitigate risks to rare disease clinical programmes
      • Leveraging historical data for use in rare disease trials
      • Natural history studies to improve drug development in rare diseases
      • Patient Centricity in Orphan Drug Development
      • The key to remarkable rare disease registries
      • Therapeutic spotlight: Precision medicine considerations in rare diseases
  • Transforming Trials
    • Accelerating biotech innovation from discovery to commercialisation
    • Demystifying the Systematic Literature Reviews
    • Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
    • Linguistic validation of Clinical Outcomes Assessments
    • Optimising biotech funding
    • Adaptive clinical trials
      • Adaptive Design: The Faster Path to Market
    • Best practices to increase engagement with medical and scientific poster content
    • Decentralised clinical trials
      • Biopharma perspective: the promise of decentralised models and diversity in clinical trials
      • Decentralised and Hybrid clinical trials
      • Practical considerations in transitioning to hybrid or decentralised clinical trials
      • Navigating the regulatory labyrinth of technology in decentralised clinical trials
    • eCOA implementation
    • Blended solutions insights
      • Clinical trials in Japan: An enterprise growth and management strategy
      • How investments in supply of CRAs is better than competing with the demand for CRAs
      • The evolution of FSP: not just for large pharma
      • Embracing a blended operating model
      • Observations in outsourcing: Survey results show a blended future
    • Implications of COVID-19 on statistical design and analyses of clinical studies
    • Improving pharma R&D efficiency
    • Increasing Complexity and Declining ROI in Drug Development
    • Innovation in Clinical Trial Methodologies
    • Partnership insights
      • Exploring partnership culture and its impact on outsourcing and operational strategy
    • Risk Based Quality Management
    • Transforming the R&D Model to Sustain Growth
    • Behind Biotech: Stories of science and resilience
  • Value Based Healthcare
    • Strategies for commercialising oncology treatments for young adults
    • US payers and PROs
    • Accelerated early clinical manufacturing
    • Cardiovascular Medical Devices
    • CMS Part D Price Negotiations: Is your drug on the list?
    • COVID-19 navigating global market access
    • Ensuring scientific rigor in external control arms
    • Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
    • Health technology assessment
    • Perspectives from US payers
    • ICER’s impact on payer decision making
    • Making Sense of the Biosimilars Market
    • Medical communications in early phase product development
    • Navigating the Challenges and Opportunities of Value Based Healthcare
    • Payer Reliance on ICER and Perceptions on Value Based Pricing
    • Payers Perspectives on Digital Therapeutics
    • Precision Medicine
    • RWE Generation Cross Sectional Studies and Medical Chart Review
    • Survey results: How to engage healthcare decision-makers
    • The affordability hurdle for gene therapies
    • The Role of ICER as an HTA Organisation
    • Integrating openness and precision for competitive advantage
  • Blog
  • Videos
  • Webinar Channel

Connect with us

  • Contact us
  • Submit proposal request
  • Update Email Preferences
  • Global office locator
  • ICON on social media

Related information:

Infographic

Use of Accelerometer Based Wrist-worn Devices in Clinical Trials

Webpage

Medical Device

Webpage

Biomarkers

Site Branding
    ICON plc
  • Contact
  • About ICON
  • Results & Reports
For Clients
  • Therapeutics
  • Solutions
  • Insights
  • Technologies
  • Content preferences
  • Office locations
ICON for
  • Patients
  • Volunteers
  • Investigators
  • Jobs & Careers
  • Investors
  • Suppliers
News & Events
  • Press releases
  • Mediakit
  • Events
  • Webinars
Socials
  • Linkedin
  • Facebook
  • Instagram
  • Youtube

Legal Footer

  • © 2025 ICON plc
  • Disclaimer
  • Privacy & Data
  • Cookies
How can we help?